Get the Daily Brief
Latest Biotech News
Gepotidacin advances as oral UTI drug; gonorrhea review ongoing
Gepotidacin, an oral type II topoisomerase inhibitor marketed as Blujepa for uncomplicated urinary tract infections following its March 2025 approval, is under further regulatory review for use...
Nanopore cfDNA pinpoints tissue origin and pathogens in critical‑care plasma
Researchers adapted nanopore sequencing to analyze plasma cell‑free DNA from critically ill patients, demonstrating simultaneous tissue‑of‑origin signals and pathogen detection in a single stream...
C2S‑Scale LLM repurposes language models for single‑cell biology: pretrained on 50M profiles
A multi‑institution team released Cell2Sentence‑Scale (C2S‑Scale), a family of large language models trained on over 50 million human and mouse transcriptomes and associated annotations to...
Tetraneuron advances upstream gene‑therapy approach for Alzheimer’s: E2F4 AAV program
Tetraneuron described preclinical progress for TET‑101, an AAV‑based gene therapy targeting transcription factor E2F4 to prevent neuronal cell‑cycle re‑entry, proposing an 'upstream' approach to...
CAR‑T and CAR‑NK revive AML hopes: reviews highlight progress and challenges
A recent review mapped advances in CAR‑T and CAR‑NK cell therapies for acute myeloid leukemia, emphasizing engineered cell approaches that target AML antigens while mitigating myeloablation and...
Biogen pays $70M for Vanqua drug – Secures C5aR1 rights
Biogen announced an exclusive global license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front with up to $990 million in potential milestones. Jane Grogan, Biogen’s head...
Lilly widens gene-therapy bet – Acquires Adverum
Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum in a deal that transfers Adverum’s ocular gene‑therapy programs into Lilly’s portfolio. The transaction marks a notable...
FDA clears GSK’s Blenrep: Third-line multiple myeloma use
The U.S. Food and Drug Administration restored GSK’s antibody‑drug conjugate Blenrep to the U.S. market with a narrowed approval for third‑line treatment of multiple myeloma. The decision follows...
Inhibrx posts phase II win: Ozekibart extends PFS in chondrosarcoma
Inhibrx reported positive registrational phase II results for ozekibart (INBRX‑109) in advanced or metastatic, unresectable chondrosarcoma, showing a statistically significant improvement in...
Nanopore sequencing detects pathogens and tissue signals in plasma cfDNA
Researchers demonstrated that nanopore sequencing of plasma cell‑free DNA (cfDNA) from critically ill patients can concurrently detect pathogen sequences and tissue‑of‑origin signals from the same...
FDA greenlights elinzanetant: Nonhormonal hot‑flash therapy approved
The FDA approved elinzanetant, a nonhormonal therapy for menopausal hot flashes and night sweats, following multinational clinical trials showing symptomatic benefit. Regulators granted the new...
STING–IL6/STAT3 blockade stops breast cancer bone metastasis
Preclinical researchers reported that interrupting the STING–IL6/STAT3 signaling axis suppressed breast‑cancer bone colonization in experimental models by preventing formation of an osteoclastic...
UCSD tweaks P450s: Yeast become more efficient biofactories for plant compounds
A University of California San Diego team reported engineering strategies that optimize cytochrome P450 activity in yeast, improving production efficiency for valuable plant‑derived compounds. The...
Chugai buys kidney biotech – ICER flags rising launch prices
Chugai Pharmaceutical completed an acquisition of a kidney‑focused biotech (terms reported in industry outlets), expanding its nephrology portfolio. Separately, the Institute for Clinical and...
FDA finds unauthorized API warehouse in India: Animal infestations cited
The FDA reported discovering an unauthorized warehouse holding active pharmaceutical ingredients and finished drugs linked to Indian generic manufacturer Hetero Labs; the inspection uncovered...
Biogen bankrolls Vanqua drug: $70M upfront for C5aR1 program
Biogen struck an exclusive licensing deal with Vanqua Bio, paying $70 million up front for global rights to a preclinical C5aR1 antagonist that targets innate immune signaling. The agreement gives...
Lilly buys Adverum gene‑therapy assets – strategic push into AAV space
Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum’s assets, reinforcing the company’s commitment to AAV‑based retinal and ocular programs. The deal positions Lilly to...
FDA greenlights elinzanetant: nonhormonal option for menopausal hot flashes
The U.S. Food and Drug Administration approved elinzanetant, a nonhormonal agent shown in multinational trials to reduce the frequency and severity of menopausal hot flashes and night sweats....
Inhibrx posts win in rare bone cancer – phase II meets endpoint
Inhibrx reported positive registrational phase II results for ozekibart in advanced or metastatic, unresectable chondrosarcoma, meeting its primary endpoint with a statistically significant...
Tango PRMT5 data satisfy — paves way to pivotal pancreatic trial
Tango Therapeutics disclosed early clinical data for its next‑generation MTA‑cooperative PRMT5 inhibitor vopimetostat (TNG‑462) that showed activity in MTAP‑deleted tumors, including pancreatic...